DEER PARK, Ill., May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 20th Annual B. Riley FBR Investor Conference on Wednesday, May 22, 2019 at 1:30 p.m. PT (4:30 p.m. ET) in Beverly Hills, CA.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing the FDA’s 505(b)(2) regulatory pathway. Eton is primarily focused on liquid dosage forms including injectables, oral liquids and ophthalmics. Eton has a diversified pipeline of high-value product candidates in various stages of development and therapeutic areas, including multiple product candidates currently under review by the FDA.
Company Contact:
David Krempa
dkrempa@etonpharma.com
847-805-1077
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
Julie.Seidel@sternir.com
212-362-1200
Source: Eton Pharmaceuticals
